Survival and risk of relapse.

Overall survival (A) and relapse risk (B) in MRC AML11 trial are shown by hierarchical risk group. Outcome is shown applying the revised hierarchical risk group classification that was found to be more predictive in older adults than the original scheme devised in younger patients entered into the MRC AML10 trial. The revised risk groups were as follows. Favorable group: t(15;17), t(8;21), or inv(16), whether alone or in conjunction with other abnormalities. Intermediate group: normal karyotype, all other noncomplex abnormalities. Adverse group: complex karyotype (5 or more unrelated abnormalities), excluding cases with t(15;17), t(8;21), and inv(16).